Polyrizon
Business Services · Israel · <25 Employees
View Company Info for Free
About
Headquarters
5 Hatidhar St, Raanana, Raanana, 4366507, Israe...Phone Number
+972 93740120Website
www.polyrizon-biotech.comRevenue
<$5 MillionStock Symbol
PLRZIndustry
Most Recent Scoops
Who is Polyrizon
Polyrizon Org Chart
Is Polyrizon your ideal customer?
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Polyrizon has new funding data
Earning: See what the market has to say on Polyrizon recently announced quarterly report
Click to see if Polyrizon had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Polyrizon
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Polyrizon launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Polyrizon, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Polyrizon is spiking on competitors!
Check if Polyrizon has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Polyrizon Employee Growth Rate
Percentage of growth
1st year Mask
2nd year Mask
Polyrizon Tech Stack
A closer look at the technologies used by Polyrizon
Most Recent Scoops
Polyrizon News & Media
Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs
Raanana, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announce today the appointment of Dr. Michal Meir, Senior Consultant at MedTech SME Ltd., as Senior Director of Regulatory and Clinical Affairs. The appointment was made as part of the Company’s preparations towards its clinical trial for PL-14 that is expected to commence in 2025.Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker
The engagement with an EU-based GMP manufacturing facility enables timely production and preparation for clinical trial. The EU-based GMP manufacturer has large-scale commercial production capabilities, to support Polyrizon in future commercialization effortsPolyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance
Raanana, Israel, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announces today the appointment of Asaf Azulay, the Managing Director of Eurofins’ Li-Med team, to its leadership as its VP of Regulatory Affairs and Quality Assurance (RA/QA). This strategic appointment reflects Polyrizon’s ongoing commitment to maintaining the highest industry staPolyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
The engagement with an EU-based GMP manufacturing facility enables timely production and preparation for clinical trial. The EU-based GMP manufacturer has large-scale commercial production capabilities, to support Polyrizon in future commercialization efforts
Frequently Asked Questions Regarding Polyrizon
Polyrizon is a biotech company, focused on the development and commercialization of innovative intranasal products.... Read More